FGFR3 and urinary bladder carcinoma: On this basis, the combination of FGFR3, TERT, and HRAS proto-oncogene mutations resulted in a sensitivity of 93% and a specificity of 89% for the diagnosis of bladder cancer, which shows that the combination of DNA methylation testing has great potential in the detection of bladder cancer.